Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 GBX | 0.00% | +3.23% | -50.00% |
04-26 | Evgen Pharma plc will Change its Ticker to TCF from EVG | CI |
04-26 | Evgen Pharma plc will Change its Name to TheraCryf plc | CI |
Sales 2024 * | 486K 664K | Sales 2025 * | - | Capitalization | 4.26M 5.82M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.47M | Net income 2025 * | - | EV / Sales 2024 * | 4.26 x |
Net cash position 2024 * | 2.19M 2.99M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.63
x | P/E ratio 2025 * |
-
| Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.58% |
1 week | +3.23% | ||
Current month | -8.57% | ||
1 month | -8.57% | ||
3 months | -56.76% | ||
6 months | -58.97% | ||
Current year | -50.00% |
Managers | Title | Age | Since |
---|---|---|---|
Huw Jones
CEO | Chief Executive Officer | 62 | - |
Toni Haenninen
DFI | Director of Finance/CFO | - | 23-09-04 |
Glen Clack
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Huw Jones
CEO | Chief Executive Officer | 62 | - |
Susan Foden
CHM | Chairman | 71 | 14-11-20 |
Alan Barge
BRD | Director/Board Member | - | 15-10-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.8 | 0.00% | 144,977 |
24-04-25 | 0.8 | 0.00% | 0 |
24-04-24 | 0.8 | 0.00% | 227,410 |
24-04-23 | 0.8 | 0.00% | 1,405,000 |
24-04-22 | 0.8 | +3.23% | 5,910,542 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-50.00% | 4.26M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- EVG Stock